Promega Corporation Launches Novel ADCC Reporter Bioassay for Biologics
10/10/2012 10:01:56 AM
MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announces the introduction of a novel bioluminescent assay for the quantification of Fc effector function of antibody-based molecules in the development and manufacture of biologic drugs. The assay is ADCC mechanism of action (MOA)-based and features frozen, thaw-and-use effector cells, and optimized reagents and protocol to perform a reporter-based ADCC bioassay in a single day. The ADCC Reporter Bioassay correlates with classic cytotoxic ADCC assays and is a suitable replacement for these cumbersome and highly variable assays.